Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
山本 風海; 山川 恵美*; 高柳 智弘; 三木 信晴*; 神谷 潤一郎; Saha, P. K.; 吉本 政弘; 柳橋 亨*; 堀野 光喜*; 仲野谷 孝充; et al.
ANS RPSD 2018; 20th Topical Meeting of the Radiation Protection and Shielding Division of ANS (CD-ROM), 9 Pages, 2018/08
J-PARC 3GeVシンクロトロンは1MWのビーム出力を中性子ターゲットおよび主リングシンクロトロンに供給するためにビーム調整を進めている。現在は最大500kWの出力で運転を行っているが、現状最も放射化し線量が高い箇所はリニアックからのビーム軌道をシンクロトロンに合流させる入射部である。この放射化はビーム入射に使用する荷電変換フォイルとビームの相互作用によるものであるが、フォイルを使う限り必ず発生するため、周辺作業者への被ばくを低減するための遮蔽体を設置できる新しい入射システムの検討を行った。フォイル周辺は入射用電磁石からの漏れ磁場で金属内に渦電流が流れ、発熱することがこれまでの経験から判っているため、その対策として金属の遮蔽体を層状に分け、その間に絶縁体を挟む構造を考案した。遮蔽計算の結果から、9mmのステンレスの間に1mmの絶縁体を挟んでも遮蔽性能は5%程度しか低下しないことがわかった。
Cu labeled monoclonal antibodyPaudyal, P.*; Paudyal, B.*; 飯田 靖彦*; 花岡 宏史*; 渡辺 智; 石岡 典子; 渡邉 茂樹; 高柳 恵美*; 吉岡 弘樹*; 織内 昇*; et al.
no journal, ,
Quantitative PET imaging using Cu labeled antibody was investigated by animal study. Anti CD20 antibody, NuB2 was conjugated with the chelator, DOTA and radiolabeled with Cu. For animal study, nude mice bearing lymphoma (Raji tumor) were injected with Cu-DOTA-NuB2. The PET imaging followed by the biodistribution studies were done at 10min, 24h and 48h post injection. PET imaging showed the significant Cu-DOTA-NuB2 accumulations in the tumor. Biodistribution studies also revealed the significant uptake in tumor than that in muscle region at any time point. This study demonstrated the utility of Cu labeled antibody as a diagnostic imaging agent for PET and the success can be translated into clinic for the quantitative targeted imaging with PET.
飯田 靖彦*; 花岡 宏史*; 吉岡 弘樹*; 高柳 恵美*; 渡邉 茂樹; 石岡 典子; 渡辺 智; 松橋 信平; Paudyal, P.*; 樋口 徹也*; et al.
no journal, ,
Some new radionuclides would be useful for cancer diagnosis and therapy. Our project is to prepare these radionuclides, to apply them to many radiopharmaceuticals and to investigate usefullness of those new radiopharmaceuticals. Radio immuno therapy (RIT) is one of the most promising treatments for cancer therapy. And assessment of radiation dose to both tumor and normal tissues is very important to RIT. PET can estimate radiation dose directly, but general positron emittors don't suit for labeling of antibody because of their short half-lives. Cu and 
Br have appropriate properties (Cu: T
= 12.7 hr, Br: T = 16.1 hr) and they may have great potentials for immuno-PET. We have synthesized Cu or Br labeled monoclonal antibody and evaluated potentials for in vivo quantitative evaluation of RIT. And we synthesized Br labeled glucose (BrDG). We evaluated its utility for tumor diagnosis. These new radiopharmaceuticals are very useful for cancer diagnosis and therapy. We will develop various radiopharmaceuticals labeled with these new radionuclides and apply them to clinical medicine in future.
Cu labeled trastuzumab in Her2/neu overexpressing non-small cell lung cancer xenograftsPaudyal, P.*; Paudyal, B.*; 飯田 靖彦*; 花岡 宏史*; 渡辺 智; 石岡 典子; 渡邉 茂樹; 高柳 恵美*; 吉岡 弘樹*; 織内 昇*; et al.
no journal, ,
Non-small cell lung carcinoma (NSCLC) overexpress Her2/neu gene in approximately 20% of the cases. Trastuzumab a humanized monoclonal antibody targets Her2/neu and inhibits neoplastic cell proliferation and significantly increases survival of patients with advanced metastatic breast cancer. The present study aimed to determine the effect of trastuzumab in Her2/neu expressing NSCLC with Cu labeled trastuzumab using in vivo PET imaging. Imaging of Her2/neu expression was performed with Cu -DOTA- trastuzumab in H2170 tumor bearing mouse with PET. PET studies revealed relatively high accumulation of Cu -DOTA- trastuzumab in the Her2/neu overexpressing H2170 tumor at 48 h post injection. The success of Cu -DOTA- trastuzumab brought an insight to PET imaging of Her2/neu gene expression in NSCLC patients with Cu -DOTA- trastuzumab to define the patients who might be benefited with trastuzumab based therapy.